Whole-Pelvis Radiotherapy in Combination With Interstitial Brachytherapy: Does Coverage of the Pelvic Lymph Nodes Improve Treatment Outcome in High-Risk Prostate Cancer?

International Journal of Radiation Oncology Biology Physics

Volumn 76, Issue 4, 2010, Pages 1078-1084

  Bittner, Nathan ^a   Merrick, Gregory S ^b   Wallner, Kent E ^c   Butler, Wayne M ^b   Galbreath, Robert ^b   Adamovich, Edward ^d  

^a Tacoma/Valley Radiation Oncology Centers   (United States)

^b WHEELING JESUIT UNIVERSITY   (United States)

^c DEPARTMENT OF VETERANS AFFAIRS   (United States)

^d WHEELING HOSPITAL   (United States)

Author keywords

Androgen deprivation therapy; Brachytherapy; Prostate cancer; Whole pelvic radiotherapy

Indexed keywords

ANDROGEN DEPRIVATION THERAPY; BRACHYTHERAPY; CAUSE-SPECIFIC SURVIVAL; CONCENTRATION OF; DEPRIVATION THERAPY; EXTERNAL BEAM RADIATION; GLEASON SCORES; INTERSTITIAL BRACHYTHERAPY; MULTI VARIATE ANALYSIS; OVERALL SURVIVAL RATES; PELVIC LYMPH NODES; PROGRESSION FREE SURVIVAL; PROSTATE CANCERS; PROSTATE SPECIFIC ANTIGEN; TREATMENT OUTCOMES; WHOLE PELVIC RADIOTHERAPY; WHOLE-PELVIS RADIOTHERAPY;

BIOPSY; DECISION MAKING; MULTIVARIANT ANALYSIS; ONCOLOGY; PATIENT MONITORING;

RADIOTHERAPY;

ANTIANDROGEN; GONADORELIN AGONIST; IODINE 125; PALLADIUM 103; PROSTATE SPECIFIC ANTIGEN;

AGED; ANDROGEN DEPRIVATION THERAPY; ARTICLE; BRACHYTHERAPY; CANCER RADIOTHERAPY; CAUSE SPECIFIC SURVIVAL; CONTROLLED STUDY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE CANCER; RADIATION DOSE; RADIATION FIELD; TREATMENT OUTCOME;

AGED; ANALYSIS OF VARIANCE; BRACHYTHERAPY; DISEASE-FREE SURVIVAL; FOLLOW-UP STUDIES; HUMANS; LYMPHATIC IRRADIATION; MALE; PELVIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 77449108891     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.02.069     Document Type: Article

References (25)

1. Nguyen P. D'Amico A. Targeting pelvic lymph nodes in men with intermediate- and high-risk prostate cancer despite two negative randomized trials. J Clin Oncol 26 (2008) 2055-2056
2. Roach M. Targeting pelvic lymph nodes in men with intermediate- and high-risk prostate cancer, and confusion about the results of the randomized trials. J Clin Oncol 26 (2008) 3816-3817
3. Roach M., DeSilvio M., Lawton C., et al. Phase III trial comparing whole-pelvic versus prostate only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 21 (2003) 1904-1911
4. Lawton C., DeSilvio M., Roach M., et al. An update of the phase III trial comparing whole-pelvic (WP) to prostate only (PO) radiotherapy and neoadjuvant to adjuvant total androgen suppression (TAS): Updated analysis of RTOG 94-13, with emphasis on unexpected hormone/radiation interactions. Int J Radiat Oncol Biol Phys 69 (2007) 646-655
5. Pommier P., Chabaud S., Lagrange J., et al. Is there a role for pelvic irradiation in localized prostate adenocarcinoma? Preliminary results of GETUG-01. J Clin Oncol 25 (2007) 5366-5373
6. Pollack A., Zagars G., Smith L., et al. Preliminary results of a randomized radiotherapy dose-escalation study comparing 70 Gy with 78 Gy for prostate cancer. J Clin Oncol 18 (2000) 3904-3911
7. Kuban D., Tucker S., Dong L., et al. Long-term results of the M.D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 70 (2008) 67-74
8. Zelefsky M., Fuks Z., Hunt M., et al. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 166 (2001) 876-881
9. Bittner N., Merrick G., Wallner K., et al. Interstitial brachytherapy should be standard of care for treatment of high-risk prostate cancer. Oncology 22 (2008) 995-1004
10. Stock R., Ho A., Cesaretti J., et al. Changing the patterns of failure for high-risk prostate cancer patients by optimizing local control. Int J Radiat Oncol Biol Phys 66 (2006) 389-394
11. Stock R., Cahlon O., Cesaretti J., et al. Combined modality treatment in the management of high-risk prostate cancer. Int J Radiat Oncol Biol Phys 59 (2004) 1352-1359
12. Dattoli M., Wallner K., True L., et al. Long-term outcomes after treatment with brachytherapy and supplemental conformal radiation for prostate cancer patients having intermediate and high-risk features. Cancer 110 (2007) 551-555
13. Merrick G., Butler W., Lief J., et al. Biochemical outcomes for hormone-naïve patients with high-risk prostate cancer managed with permanent interstitial brachytherapy and supplemental external-beam radiation. Cancer J 8 (2002) 322-327
14. Sylvester J., Grimm P., Blasko J., et al. 15-Year biochemical relapse free survival in clinical T1-T3 prostate cancer following combined external beam radiotherapy and brachytherapy: Seattle experience. Int J Radiat Oncol Biol Phys 67 (2007) 57-64
15. Bittner N., Merrick G., Galbreath R., et al. Primary causes of death after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 72 (2008) 433-440
16. D'Amico A., Whittington R., Malkowicz S., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 (1998) 969-974
17. Merrick G.S., Butler W.M., Wallner K.E., et al. Extracapsular radiation dose distribution following permanent prostate brachytherapy. Am J Clin Oncol 26 (2003) E178-E189
18. Merrick G.S., and Butler W.M. Modified uniform seed loading for prostate brachytherapy: Rationale, design and evaluation. Tech Urol 6 (2000) 78-84
19. Partin A., Mangold L., Lamm D., et al. Contemporary update of prostate cancer staging nomograms (Partin tables) for the new millennium. Urology 58 (2001) 843-848
20. Schild S. Elective nodal irradiation (ENI) does not appear to provide a clear benefit for patients with unresectable non-small-cell lung cancer (NSCLC). Int J Radiat Oncol Biol Phys 72 (2008) 311-312
21. Yuan S., Sun X., Li M., et al. A randomized study of involved-field radiation versus elective nodal irradiation in combination with concurrent chemotherapy for inoperable stage III nonsmall cell lung cancer. Am J Clin Oncol 30 (2007) 239-244
22. Radiation Therapy Oncology Group (RTOG) protocol 0617. www.rtog.org.
23. Eifel P., Winter K., Morris M., et al. Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin Oncol 22 (2004) 872-880
24. Rose P., Bundy B., Watkins E., et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med 340 (1999) 1144-1153
25. Keys H., Bundy B., Stehman F., et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 340 (1999) 1154-1161